Free Trial

Bristol Myers Squibb (BMY) Competitors

Bristol Myers Squibb logo
$47.46 +0.97 (+2.08%)
As of 11:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BMY vs. AMGN, EXEL, GILD, MRNA, VRTX, ABBV, JNJ, LLY, MRK, and PFE

Should you be buying Bristol Myers Squibb stock or one of its competitors? The main competitors of Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.

Bristol Myers Squibb vs. Its Competitors

Amgen (NASDAQ:AMGN) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.2%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 92.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Amgen had 9 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 50 mentions for Amgen and 41 mentions for Bristol Myers Squibb. Amgen's average media sentiment score of 1.15 beat Bristol Myers Squibb's score of 1.11 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
45 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bristol Myers Squibb
32 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Amgen has a net margin of 17.39% compared to Bristol Myers Squibb's net margin of 11.38%. Amgen's return on equity of 176.11% beat Bristol Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen17.39% 176.11% 12.39%
Bristol Myers Squibb 11.38%87.62%15.98%

Amgen currently has a consensus target price of $307.82, indicating a potential upside of 3.63%. Bristol Myers Squibb has a consensus target price of $58.00, indicating a potential upside of 21.97%. Given Bristol Myers Squibb's higher possible upside, analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.35
Bristol Myers Squibb
2 Sell rating(s)
13 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.32

Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Bristol Myers Squibb has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Amgen has higher earnings, but lower revenue than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$33.42B4.78$4.09B$10.9627.10
Bristol Myers Squibb$47.64B2.03-$8.95B$2.6717.81

Summary

Amgen beats Bristol Myers Squibb on 14 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMY vs. The Competition

MetricBristol Myers SquibbMED IndustryMedical SectorNYSE Exchange
Market Cap$96.78B$2.90B$5.50B$20.45B
Dividend Yield5.29%2.44%5.24%3.72%
P/E Ratio17.8120.8727.1727.80
Price / Sales2.03190.94376.8948.54
Price / Cash7.9741.7026.2118.22
Price / Book5.897.447.984.58
Net Income-$8.95B-$55.04M$3.17B$982.91M
7 Day Performance0.13%4.41%3.04%1.24%
1 Month Performance-1.79%1.58%2.38%4.89%
1 Year Performance18.88%4.62%33.64%14.21%

Bristol Myers Squibb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMY
Bristol Myers Squibb
4.9201 of 5 stars
$47.55
+2.3%
$58.00
+22.0%
+17.2%$96.78B$47.64B17.8134,100Positive News
AMGN
Amgen
4.5056 of 5 stars
$277.23
+0.0%
$307.82
+11.0%
-5.8%$149.07B$33.42B25.2928,000Positive News
EXEL
Exelixis
4.7335 of 5 stars
$43.96
+0.7%
$43.56
-0.9%
+99.8%$11.99B$2.17B19.981,147Options Volume
GILD
Gilead Sciences
4.8331 of 5 stars
$110.44
-0.2%
$110.55
+0.1%
+67.6%$137.38B$28.74B23.2517,600Positive News
MRNA
Moderna
4.3656 of 5 stars
$27.69
+2.0%
$46.61
+68.3%
-74.7%$10.71B$3.24B-3.175,800
VRTX
Vertex Pharmaceuticals
4.4285 of 5 stars
$445.60
+1.0%
$511.62
+14.8%
-3.2%$114.43B$11.02B-113.676,100Positive News
ABBV
AbbVie
4.9416 of 5 stars
$184.27
+1.1%
$211.29
+14.7%
+12.1%$325.49B$56.33B78.4155,000Trending News
Analyst Revision
JNJ
Johnson & Johnson
4.8395 of 5 stars
$151.59
-0.5%
$170.88
+12.7%
+6.0%$364.74B$88.82B16.86138,100Positive News
LLY
Eli Lilly and Company
4.9869 of 5 stars
$777.10
+0.2%
$1,011.61
+30.2%
-15.5%$736.49B$45.04B63.2347,000Trending News
Options Volume
MRK
Merck & Co., Inc.
4.9969 of 5 stars
$78.92
-0.2%
$109.19
+38.4%
-36.0%$198.17B$63.92B11.4975,000Positive News
PFE
Pfizer
4.9739 of 5 stars
$24.18
0.0%
$29.17
+20.6%
-10.1%$137.47B$63.63B17.5281,000Positive News

Related Companies and Tools


This page (NYSE:BMY) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners